-
Maresca uncertain over Rodri's future at Man City
-
Hotter Europe isn't cooling investor fervor for stocks
-
MEXC's August 2026 Proof of Reserves Confirms User Assets Fully Backed as Reserve Ratios Remain Above 100%
-
Duplantis into pole vault final at Euros
-
Zambia suspends vote counting nationwide citing violence
-
Maresca says 'anything can happen' amid talk of Rodri move to Barcelona
-
Coe pledges court showing to defend World Athletics over Russia stance
-
Indonesian leader vows to shut over 750 'unproductive' state-owned firms
-
Stocks mixed as oil climbs, dollar drops
-
NATO jets shoot down drone in Latvian airspace: spokesperson
-
Tourists beat the heat with 'magical' Colosseum night tours
-
Wildfire forces hundreds to flee in western Germany
-
Spain extends largest nuclear plant in policy U-turn
-
Croatian wildfire forces thousands to flee, injures dozens
-
Gill says 'huge honour' to lead India in 600th Test
-
Latest developments: Europe battles wildfires
-
Brazilian police recover Matisse works stolen in 2025
-
Is a new conflict brewing in northern Ethiopia?
-
Exiled Putin critic says push for peace put him in danger
-
UK firefighters 'under pressure' as multiple blazes rage
-
EU to study potential vaccine for Lyme disease: companies
-
ARKBRIDGE Reaches 50,000 Clients and Launches New Referral Rewards Program
-
Colombia vows to find all missing quake victims as rescue hopes fade
-
New wildfire forces evacuation of 500 people in France
-
Farage wins UK by-election as Count Binface claims 'moral victory'
-
ट्रोजन: एक अधिक खतरनाक राजनीतिक युग के लिए विशेष सुरक्षा
-
TROJAN: 더욱 위험해진 정치 시기를 위한 특별 보호 조치
-
『TROJAN』:政治情勢がより危険になる時代に向けた特別な保護策
-
《特洛伊木馬》:在政治局勢日趨險惡的時代,提供特別保護
-
برنامج «TROJAN»: حماية خاصة في ظل أوقات سياسية أكثر خطورة
-
TROJAN: спеціальний захист для більш небезпечних політичних часів
-
TROJAN: Special protection for a more perilous political era
-
Thai schools step up security after deadly shooting
-
Tanzid makes history as Bangladesh dominate first Australia Test
-
Thousands stranded as heavy rain kills at least four in Japan
-
Indonesia to close more than 750 state-owned enterprises
-
McIntosh bounces back with 400m medley win at Pan Pacs
-
US backs Japan over Putin trip to disputed islands
-
Farage declares victory as count still underway in UK by-election
-
'I want to be Eala': Philippine sensation sparks tennis boom at home
-
Australia probes three near-misses at Sydney Airport
-
US says lower oil prices, not Iran's nuclear program, are now top priority in war
-
Classy Tanzid puts Bangladesh in firm charge against Australia
-
Most Asian stocks track Wall St record as US data ease rate fears
-
Schwarber smacks two homers to power Philles' MLB Field of Dreams win
-
China's viral 'spicy strips' take a bite of global snack market
-
Pakistan's date workers toil through rising heat
-
Shelton does the double in Canada
-
New trend of injecting banned peptides to 'optimise' body
-
'Shock' gloves for US immigration agents fuel potential abuse fears
Japan biochemist who discovered statins, Akira Endo, dies
Japanese biochemist Akira Endo, who discovered cholesterol-lowering statins, has died aged 90, his former student and colleague said on Tuesday.
Statins, which can prevent heart attacks or strokes, are among the most commonly prescribed drugs worldwide.
Keiji Hasumi, a professor who was a long-time associate of Endo, said the scientist had died on June 5.
"His work was truly great. Statins didn't exist before Endo," Hasumi told AFP. "It has the same value and impact as the discovery of penicillin."
Johns Hopkins Medicine says more than 200 million people take statins. Studies say the global market for them was worth $15 billion in 2023 and is expected to grow.
Endo experimented on thousands of microbes to reach his 1973 discovery of mevastatin -- an agent derived from penicillin that reduces so-called "bad" cholesterol in the blood.
The researcher "was a tough, strict person. He was insightful and perceptive," and "able to see the hidden essence of things", Hasumi said.
Endo was born in 1933 to a farming family in rural northern Japan.
His ambitions began early thanks to his grandfather, who was interested in medicine and became a "great home teacher", Endo said in a 2008 autobiographical essay.
As a student, Endo became interested in antibiotics like penicillin, "deeply impressed" by how many lives they had saved, his essay in the journal Nature Medicine said.
Endo carried out research in New York in the late 1960s, when coronary heart disease was the main cause of US deaths.
"I often saw ambulances coming to take elderly people who had suffered a heart attack to hospital", which "made me realise the importance of developing a cholesterol-lowering drug", he said.
Endo worked at the Tokyo University of Agriculture and Technology, which issued a statement expressing condolences over his death, and at Japanese drugmaker Sankyo, now a part of Daiichi-Sankyo.
He spent two years testing 6,000 strains of microbe in the search for a new drug that could help achieve his goal before finally finding mevastatin.
Conflicting reports on the benefits and potential harms of statins in recent years have prompted some people prescribed the drugs to stop taking them.
"Are statins safe? For most people, the answer is a resounding yes, according to a 2014 Johns Hopkins meta-analysis of 20 years worth of published research," the US university says.
Endo was a strong candidate for a Nobel Prize, but never won. In a report on his death, Japanese broadcaster NHK noted Endo had received other accolades, including being honoured as a Person of Cultural Merit by the government in 2011.
His discovery "was the result of many twists and turns", Hasumi said.
"He reached his goal by overcoming so many challenges, without which medicines cannot be created, I think I remember him saying."
K.Hassan--SF-PST